MN-CWT
CWT, the Business-to-Business-for-Employees (B2B4E) travel management platform, announces that Michelle McKinney Frymire has decided to step down from her roles at the Company. As part of the Company’s long-term succession planning process, the Board of Directors has appointed President and Chief Commercial Officer Patrick Andersen as its next President and Chief Executive Officer, effective May 1, 2022. He will also serve on the Company’s Board of Directors.
“Leading CWT through such a critical phase in its evolution has been a great honor,” said McKinney Frymire. “We have made substantial achievements during extraordinary times, and I am grateful to our global team and customers for their trust and supportive partnership. Now, with a strong financial foundation in place, CWT is positioned to accelerate its growth plan and I’m pleased to pass the baton to Patrick.”
“We are excited that Patrick will serve as our next CEO, given his outstanding track record as Chief Commercial Officer and 13 years in international leadership roles at CWT. He has deep-rooted relationships with our customers and stakeholders and has demonstrated superb leadership through overseeing our strategic priorities, expanding RoomIt, and launching our groundbreaking myCWT China technology platform,” said Jim Abrahamson, Chair of the CWT Board. “On behalf of the Board and our global colleagues, we thank Michelle for her many contributions since she joined the Company in 2019 and wish her well in her next endeavors.”
“I’m delighted and honored to lead CWT to its next stage of growth,” said Patrick Andersen. “As travel demand increases, CWT is well positioned to invest in and expand its industry leadership and global relationships. Importantly, I’ll continue our commitment to our core values and look forward to working with our Board and the CWT team to enhance our technology, and further strengthen the travel and events services we provide to our customers around the world.”
Prior to his role as President and Chief Commercial Officer, Mr. Andersen served as Chief Strategy Officer and before that President of the Americas. Since joining the Company in 2008, Mr. Andersen has managed and overseen several industry-defining initiatives including the launch of myCWT China, expanding RoomIt by CWT, and developing innovative long-term GDS technology partnership agreements. He has over 30 years’ experience in global travel & logistics, with various international leadership roles at Deutsche Post Worldwide and DHL. Andersen also serves as a Non-Executive Member of the Board at Global Minnesota, and MNSNAP, and is on the Board of Overseers for the Carlson School of Management. He studied management at the London Business School.
About CWT
CWT is a Business-to-Business-for-Employees (B2B4E) travel management platform on whom companies and governments rely on to keep their people connected. Anywhere, anytime, anyhow – across six continents – the company provides their clients and their employees with innovative technology and an efficient, safe, and secure travel experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom